Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Milestone Pharmaceuticals ( (MIST) ) is now available.
On January 26, 2026, Milestone Pharmaceuticals announced that CARDAMYST (etripamil) nasal spray, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia, became available through U.S. retail pharmacies following its December 12, 2025 FDA approval, marking the first new PSVT therapy in more than three decades. The company is executing a rapid commercial rollout that includes deploying a national sales force in mid-February 2026 and launching a comprehensive patient assistance program with benefits verification, reimbursement support, and an expected $25 copay cap for eligible commercially insured patients, a strategy that could significantly expand access, reduce emergency department reliance, and strengthen Milestone’s position in the cardiovascular therapeutics market.
The most recent analyst rating on (MIST) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Neutral.
The score is held back primarily by weak financial performance (no current revenue, widening losses, and significant cash burn with elevated leverage). Offsetting this, corporate events are strongly positive, highlighted by FDA approval, progress in Europe, and meaningful non-dilutive financing. Technical indicators remain weak-to-neutral and do not yet confirm a sustained positive trend, while valuation is difficult to assess given negative earnings and no dividend.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines for patients with certain heart conditions. Its lead product is CARDAMYST (etripamil) nasal spray, a novel calcium channel blocker approved by the U.S. Food and Drug Administration for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults, with etripamil also in development for atrial fibrillation with rapid ventricular rate (AFib-RVR).
Average Trading Volume: 5,292,056
Technical Sentiment Signal: Hold
Current Market Cap: $168.6M
See more insights into MIST stock on TipRanks’ Stock Analysis page.
